(P079) Retrospective Review of Chemoradiation in the Preoperative or Definitive Management of Locally Advanced Vulvar Cancer

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

This treatment schema provided excellent tolerance with sustained local control. All patients obtained cCR and were able to avoid pelvic exenteration surgery and maintain preservation of bladder and rectal function.

Melissa Joyner, MD, Gwyn Richardson, MD, Lyuba Levine, Sandra Hatch; UT Medical Branch, Galveston

OBJECTIVES: To review historical use of preoperative chemoradiotherapy at a single institution in patients with locally advanced vulvar cancer who were not surgical candidates due to extent of disease. Patients were treated with intent to improve local control with organ preservation.

METHODS: Historical chart review of 12 patients with an average age of 52 years (range: 40–72 yr) treated between 1997 and 2014, all with locally advanced clinical stage T3 or T4 squamous cell carcinomas of the vulva not amenable to surgical resection. A total of 2 of 12 patients presented with locally advanced recurrent disease and nodal relapse. All patients were treated with external beam to 4,760 cGy (1.7 Gy per fraction × 28 fractions) using an accelerated fractionation schema consistent with the Gynecologic Oncology Group (GOG) 101 protocol with a planned treatment break in conjunction with concurrent cisplatin and 5-fluorouracil (5-FU). A single patient treated with a modified fractionation schema after the first cycle of radiation demonstrated superior treatment response, which facilitated surgical resection; this patient was then followed with additional radiation to treat residual microscopic disease. Further, 7 out of 12 patients (58.3%) also received a boost ranging from 7.2 Gy to 17.2 Gy, with a single patient receiving 12 Gy standard deviation [SD] via vaginal cylinder.

RESULTS: The study patients had an average of 75 months of follow-up. Sustained local control was achieved in 8 of 12 patients (66.7%). A complete clinical response (cCR) was seen in 100% of patients following treatment. Despite extensive disease at presentation, only 2 of 12 patients (16.7%) failed in the vulva. A significant number of patients remained disease-free with no evidence of distant metastases (58%)-5 of 12 patients were alive without any disease, and an additional 2 of 12 expired without evidence of disease. While 2 out of 12 patients exhibited evidence of active disease, they are alive and undergoing additional therapy. Only 2 of 12 patients to date have expired with evidence of disease, and 1 patient expired with disease status unknown. Biopsies only were done of the primary and/or node in 4 of 12 patients (33%), which were negative for disease. Organ preservation was achieved in 100% of patients.

CONCLUSIONS: This treatment schema provided excellent tolerance with sustained local control. All patients obtained cCR and were able to avoid pelvic exenteration surgery and maintain preservation of bladder and rectal function.

Proceedings of the 97th Annual Meeting of the American Radium Society- americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Patients with locally advanced or metastatic urothelial cancer and visceral disease may particularly benefit from enfortumab vedotin plus pembrolizumab, according to Amanda Nizam, MD.
High-grade adverse effects with zanidatamab plus palbociclib and fulvestrant seem to be uncommon in patients with HER2-positive, hormone receptor–positive, metastatic breast cancer, according to Sara Hurvitz, MD, FACP.
Black male patients with breast cancer appear to experience worse survival outcomes compared with White patients when controlling for clinicopathological variables, according to Jason (Jincong) Q. Freeman, MPH, MS.
Results from the ECOG-ACRIN E4112 trial appear to support the use of DCIS scores for identifying patients with breast cancer who may be eligible to omit radiotherapy following MRI-guided surgery.
Providers should inform patients with breast cancer that selecting later-line therapies following prior treatment with CDK4/6 inhibitors is a “developing area,” says Abigail M. Johnston, JD.
Data from the phase 3 NATALEE trial highlight a positive toxicity profile for ribociclib as an adjuvant therapy for patients with hormone receptor–positive, HER2-negative breast cancer, says Neil M. Iyengar, MD.
Future research will focus on ctDNA dynamics change over time in the full translational cohort of patients with hormone receptor–positive breast cancer in the phase 3 monarchE study, says Stephanie L. Graff, MD.
Findings from a National Cancer Database analysis highlight no statistically significant differences in survival outcomes with chemotherapy for patients over 81 years old with triple-negative breast cancer compared with those who do not receive chemotherapy.
Related Content